Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 May;35(5):801–807. doi: 10.1128/aac.35.5.801

Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys.

E M Cretton 1, R F Schinazi 1, H M McClure 1, D C Anderson 1, J P Sommadossi 1
PMCID: PMC245110  PMID: 1854160

Abstract

The pharmacokinetics and metabolism of 3'-azido-3'-deoxythymidine (AZT) were investigated in rhesus monkeys after subcutaneous administration of 33.3 mg of AZT per kg of body weight alone or in the presence of 100 mg of probenecid per kg. In addition to unchanged drug, two catabolites, 5'-O-glucuronide (GAZT) and 3'-amino-3'-deoxythymidine (AMT), were detected in plasma within 30 min. GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h. Approximately 90% of the total administered dose was recovered in urine within 24 h as AZT, GAZT, AMT, and the 5'-O-glucuronide of AMT. AZT and AMT demonstrated similar cerebrospinal fluid (CSF) penetration 1 h after AZT treatment, while GAZT poorly crossed the blood-brain barrier. Concomitant administration of probenecid greatly altered the pharmacokinetics of AZT, GAZT, and AMT, resulting in prolongation of their apparent elimination half-lives, increased concentrations in plasma, and marked reduction in renal clearances. In addition, the CSF/plasma concentration ratios for AZT and its catabolites were greatly increased, suggesting that probenecid inhibits efflux of AZT and its catabolites from CSF to plasma. The substantial levels of AMT in plasma suggest that this catabolite affects the pharmacodynamic properties of AZT in relation to its activity against human immunodeficiency virus replication and cytotoxicity to host cells. Enhanced AMT levels in plasma in the presence of probenecid may decrease the therapeutic efficacy of the AZT-probenecid combination.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Greenblatt D. J., Ameer B., Shader R. I. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther. 1985 Aug;234(2):345–349. [PubMed] [Google Scholar]
  2. Balis F. M., McCully C., Gough L., Pizzo P. A., Poplack D. G. Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. Antimicrob Agents Chemother. 1989 Jun;33(6):810–812. doi: 10.1128/aac.33.6.810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  4. Boudinot F. D., Schinazi R. F., Gallo J. M., McClure H. M., Anderson D. C., Doshi K. J., Kambhampathi P. C., Chu C. K. 3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses. 1990 Feb;6(2):219–228. doi: 10.1089/aid.1990.6.219. [DOI] [PubMed] [Google Scholar]
  5. Chatton J. Y., Odone M., Besseghir K., Roch-Ramel F. Renal secretion of 3'-azido-3'-deoxythymidine by the rat. J Pharmacol Exp Ther. 1990 Oct;255(1):140–145. [PubMed] [Google Scholar]
  6. Chu C. K., Schinazi R. F., Ahn M. K., Ullas G. V., Gu Z. P. Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. J Med Chem. 1989 Mar;32(3):612–617. doi: 10.1021/jm00123a018. [DOI] [PubMed] [Google Scholar]
  7. Collins J. M., Klecker R. W., Jr, Kelley J. A., Roth J. S., McCully C. L., Balis F. M., Poplack D. G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther. 1988 May;245(2):466–470. [PubMed] [Google Scholar]
  8. Collins J. M., Unadkat J. D. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989 Jul;17(1):1–9. doi: 10.2165/00003088-198917010-00001. [DOI] [PubMed] [Google Scholar]
  9. Cretton E. M., Waterhous D. V., Bevan R., Sommadossi J. P. Glucuronidation of 3'-azido-3'-deoxythymidine by rat and human liver microsomes. Drug Metab Dispos. 1990 May-Jun;18(3):369–372. [PubMed] [Google Scholar]
  10. Cretton E. M., Xie M. Y., Bevan R. J., Goudgaon N. M., Schinazi R. F., Sommadossi J. P. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol. 1991 Feb;39(2):258–266. [PubMed] [Google Scholar]
  11. Duckworth A. S., Duckworth G. W., Henderson G., Contreras G. Zidovudine with probenecid. Lancet. 1990 Aug 18;336(8712):441–441. doi: 10.1016/0140-6736(90)91988-m. [DOI] [PubMed] [Google Scholar]
  12. Fishman R. A. Blood-brain and CSF barriers to penicillin and related organic acids. Arch Neurol. 1966 Aug;15(2):113–124. doi: 10.1001/archneur.1966.00470140003001. [DOI] [PubMed] [Google Scholar]
  13. Gomeni C., Gomeni R. IGPHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res. 1978 Aug;11(4):345–361. doi: 10.1016/0010-4809(78)90017-4. [DOI] [PubMed] [Google Scholar]
  14. Good S. S., Koble C. S., Crouch R., Johnson R. L., Rideout J. L., de Miranda P. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos. 1990 May-Jun;18(3):321–326. [PubMed] [Google Scholar]
  15. Hedaya M. A., Sawchuk R. J. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J Pharm Sci. 1989 Sep;78(9):716–722. doi: 10.1002/jps.2600780903. [DOI] [PubMed] [Google Scholar]
  16. Kedar P. S., Abbotts J., Kovács T., Lesiak K., Torrence P., Wilson S. H. Mechanism of HIV reverse transcriptase: enzyme-primer interaction as revealed through studies of a dNTP analogue, 3'-azido-dTTP. Biochemistry. 1990 Apr 17;29(15):3603–3611. doi: 10.1021/bi00467a003. [DOI] [PubMed] [Google Scholar]
  17. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  18. Kornhauser D. M., Petty B. G., Hendrix C. W., Woods A. S., Nerhood L. J., Bartlett J. G., Lietman P. S. Probenecid and zidovudine metabolism. Lancet. 1989 Aug 26;2(8661):473–475. doi: 10.1016/s0140-6736(89)92087-4. [DOI] [PubMed] [Google Scholar]
  19. Langtry H. D., Campoli-Richards D. M. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Apr;37(4):408–450. doi: 10.2165/00003495-198937040-00003. [DOI] [PubMed] [Google Scholar]
  20. Laskin O. L., de Miranda P., Blum M. R. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis. 1989 Apr;159(4):745–747. doi: 10.1093/infdis/159.4.745. [DOI] [PubMed] [Google Scholar]
  21. Liebes L., Mendoza S., Wilson D., Dancis J. Transfer of zidovudine (AZT) by human placenta. J Infect Dis. 1990 Feb;161(2):203–207. doi: 10.1093/infdis/161.2.203. [DOI] [PubMed] [Google Scholar]
  22. Lin T. S., Fischer P. H., Prusoff W. H. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice. Biochem Pharmacol. 1982 Jan 1;31(1):125–128. doi: 10.1016/0006-2952(82)90250-7. [DOI] [PubMed] [Google Scholar]
  23. Lin T. S., Prusoff W. H. Synthesis and biological activity of several amino analogues of thymidine. J Med Chem. 1978 Jan;21(1):109–112. [PubMed] [Google Scholar]
  24. Morse G. D., Portmore A., Olson J., Taylor C., Plank C., Reichman R. C. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1990 Mar;34(3):394–397. doi: 10.1128/aac.34.3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Neef N. H., Tozer T. N., Brodie B. B. Application of seady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma. J Pharmacol Exp Ther. 1967 Nov;158(2):214–218. [PubMed] [Google Scholar]
  26. Petty B. G., Kornhauser D. M., Lietman P. S. Zidovudine with probenecid: a warning. Lancet. 1990 Apr 28;335(8696):1044–1045. doi: 10.1016/0140-6736(90)91116-r. [DOI] [PubMed] [Google Scholar]
  27. Resetar A., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol. 1989 May 1;38(9):1389–1393. doi: 10.1016/0006-2952(89)90177-9. [DOI] [PubMed] [Google Scholar]
  28. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  29. Schenker S., Johnson R. F., King T. S., Schenken R. S., Henderson G. I. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci. 1990 Jan;299(1):16–20. doi: 10.1097/00000441-199001000-00005. [DOI] [PubMed] [Google Scholar]
  30. Schinazi R. F., Boudinot F. D., Doshi K. J., McClure H. M. Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother. 1990 Jun;34(6):1214–1219. doi: 10.1128/aac.34.6.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Smith P. C., Langendijk P. N., Bosso J. A., Benet L. Z. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin Pharmacol Ther. 1985 Aug;38(2):121–127. doi: 10.1038/clpt.1985.146. [DOI] [PubMed] [Google Scholar]
  32. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Surbone A., Yarchoan R., McAtee N., Blum M. R., Maha M., Allain J. P., Thomas R. V., Mitsuya H., Lehrman S. N., Leuther M. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study. Ann Intern Med. 1988 Apr;108(4):534–540. doi: 10.7326/0003-4819-108-4-534. [DOI] [PubMed] [Google Scholar]
  34. de Miranda P., Burnette T. C., Good S. S. Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab Dispos. 1990 May-Jun;18(3):315–320. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES